Grown Rogue International (GRUSF) Depreciation & Amortization (CF) (2009 - 2026)
Grown Rogue International (GRUSF) posted quarterly Depreciation & Amortization (CF) of $91162.0 for Q1 2026, down 20.13% year-over-year from $114135.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$354.5 billion in Q4 2025.
Grown Rogue International (GRUSF) Depreciation & Amortization (CF) (2009 - 2026) Analysis & Trends
Grown Rogue International's Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $91162.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 20.13% year-over-year to $91162.0; the TTM figure through Mar 2026 stood at -$233.3 billion (down 189.13% YoY), while the FY2025 annual figure was $702258.0, down 29.31% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $91162.0, up from -$354.5 billion in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $261.8 billion in Q3 2024, with the low at -$354.5 billion in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $119159.0 (2025), against an average of $2.2 billion.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) tumbled 58.18% in 2022, then jumped 122.34% in 2023.
- Grown Rogue International's Depreciation & Amortization (CF) stood at $52010.0 in 2022, then jumped by 790.22% to $463002.0 in 2023, then soared by 56533133.12% to $261.8 billion in 2024, then sank by 235.44% to -$354.5 billion in 2025, then soared by 100.0% to $91162.0 in 2026.
- Business Quant data shows GRUSF's Depreciation & Amortization (CF) at $91162.0 in Q1 2026, -$354.5 billion in Q4 2025, and $121.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn | 65,650.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65,650.00 |
| Jun 30, 2026 | 65,650.00 |
| Mar 31, 2026 | 91,162.00 |
| Mar 31, 2026 | 91,162.00 |
| Dec 31, 2025 | -354.53 Bn |
| Dec 31, 2025 | -354.53 Bn |
| Sep 30, 2025 | 121.23 Bn |
| Sep 30, 2025 | 121.23 Bn |
| Jun 30, 2025 | 119,159.00 |
| Jun 30, 2025 | 119,159.00 |
| Mar 31, 2025 | 114,135.00 |
| Mar 31, 2025 | 114,135.00 |
| Sep 30, 2024 | 261.75 Bn |
| Sep 30, 2024 | 261.75 Bn |
| Jun 30, 2024 | 154,484.88 |
| Jun 30, 2024 | 154,484.88 |
| Mar 31, 2024 | 255,052.00 |
| Mar 31, 2024 | 255,052.00 |
| Oct 31, 2023 | 463,002.00 |
| Oct 31, 2023 | 463,002.00 |